Star Metro - Lir Life Sciences Announces Engagement for IR Services

The Company notes that it had intended to expend a lesser amount on IR activities; however, based on its canvass of the market, it found that the cost of digital IR services has increased, owing to the continued increase in global demand for such services, as well as the continued general weakness of the Canadian dollar relative to the Euro and U.S. Dollar, the currencies in which such services are normally priced. Management views this IR expenditure as a strategic investment to strengthen brand visibility, attract new investors, reinforce market presence, and support the Company's broader growth objective. The Company is of the view that it is in compliance with CSE Policy 7.2 as the consideration to be paid for the IR services is not based on the Company's market performance, and is, in the Company's view, reasonable and proportional to its cash resources and level of operations based on the following: following payment of the consideration, the Company has sufficient cash on hand to accomplish all of the business objectives as disclosed under Use of Available Funds in the Listing Statement, which includes advancing its GLP-1 drug development program through key pre-clinical milestones over the next 12 months. These milestones include developing and validating bioanalytical methods for both the active pharmaceutical ingredient and its novel excipient (approximately 3-12 months), conducting multi-phase Mini Pig studies to assess bioavailability, safety, pharmacokinetics, and early toxicology (with the first study occurring over 3-9 months and the second over 9-12 months), progressing formulation development and stability testing (6-12 months), and procuring the active ingredients and excipients required to support these programs (6-12 months). The Company also intends to maintain and advance its intellectual property position through ongoing licensing activities. Together, these initiatives form the foundation of the Company's near-term development plan as it advances its therapeutic candidate toward later-stage pre-clinical and future regulatory phases.

About Lir Life Sciences Corp.

Lir Life Sciences is focused on researching and developing scalable and affordable treatments for obesity using novel drug delivery methods. The company is advancing a transdermal patch and other novel delivery systems that mimic GLP-1, a naturally occurring hormone that helps regulate appetite and blood sugar. These therapies could potentially offer an alternative to injectable drugs. The goal is to improve access, adherence, and cost-efficiency in both developed and emerging markets. Lir Life Sciences aims to address the global burden of obesity with practical solutions based on established compounds and proven science.

ON BEHALF OF LIR LIFE SCIENCES CORP.,

"Edward Mills,"
Chief Executive Officer

For more information, please contact:

Edward Mills
Chief Executive Officer
Tel: +1 888 436 7772
Email: [email protected]

The CSE and Information Service Provider have not reviewed and do not accept responsibility for the accuracy or adequacy of this release.

Forward-Looking Statements Caution. This news release contains forward-looking statements, including statements regarding the Company's business plans and prospects. Forward-looking statements are often identified by terms such as "will," "may," "could," "should," "expect," "anticipate," "intend," "believe," "plan," or similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

SOURCE: Lir Life Sciences Corp.

View the original press release on ACCESS Newswire

O.Lessard--SMC